Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug;15(8):e666-e676.
doi: 10.1200/JOP.18.00796. Epub 2019 Jul 29.

Financial Costs and Burden Related to Decisions for Breast Cancer Surgery

Affiliations

Financial Costs and Burden Related to Decisions for Breast Cancer Surgery

Rachel A Greenup et al. J Oncol Pract. 2019 Aug.

Abstract

Purpose: Financial toxicity is a well-recognized adverse effect of cancer care, yet little is known about how women consider treatment costs when facing preference-sensitive decisions for breast cancer surgery or how surgical treatment choice affects financial harm. We sought to determine how financial costs and burden relate to decisions for breast cancer surgery.

Methods: Women (≥ 18 years old) with a history of breast cancer were recruited from the Army of Women and Sisters Network to complete an 88-item electronic survey. Descriptive statistics and regression analysis were used to evaluate the impact of costs on surgical decisions and financial harm after breast cancer surgery.

Results: A total of 607 women with stage 0 to III breast cancer were included. Most were white (90%), were insured privately (70%) or by Medicare (25%), were college educated (78%), and reported household incomes of more than $74,000 (56%). Forty-three percent underwent breast-conserving surgery, 25% underwent mastectomy, 32% underwent bilateral mastectomy, and 36% underwent breast reconstruction. Twenty-eight percent reported that costs of treatment influenced their surgical decisions, and at incomes of $45,000 per year, costs were prioritized over breast preservation or appearance. Overall, 35% reported financial burden as a result of their cancer treatment, and 78% never discussed costs with their cancer team. When compared with breast-conserving surgery, bilateral mastectomy with or without reconstruction was significantly associated with higher incurred debt, significant to catastrophic financial burden, treatment-related financial hardship, and altered employment. Among the highest incomes, 65% of women were fiscally unprepared, reporting higher-than-expected (26%) treatment costs.

Conclusion: Cancer treatment costs influenced decisions for breast cancer surgery, and comparably effective surgical treatments differed significantly in their risk of patient-reported financial burden, debt, and impact on employment. Cost transparency may inform preference-sensitive surgical decisions and improve patient-centered care.

PubMed Disclaimer

Conflict of interest statement

Financial Costs and Burden Related to Decisions for Breast Cancer Surgery

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jop/site/ifc/journal-policies.html.

Rachel A. Greenup

Honoraria: Novartis

Terry Hyslop

Consulting or Advisory Role: AbbVie

Travel, Accommodations, Expenses: AbbVie

Jeffrey Peppercorn

Employment: GlaxoSmithKline (I)

Stock and Other Ownership Interests: GlaxoSmithKline (I)

Research Funding: Pfizer

Stephanie B. Wheeler

Research Funding: Pfizer (Inst)

Travel, Accommodations, Expenses: Pfizer

S. Yousuf Zafar

Employment: Shattuck Laboratories (I)

Stock and Other Ownership Interests: Shattuck Laboratories (I)

Consulting or Advisory Role: Vivor, Family Reach Foundation, AIM Specialty Health, McKesson, RTI Health Solutions, Discern Health, Copernicus WCG

Research Funding: AstraZeneca (Inst)

Evan R. Myers

Consulting or Advisory Role: Merck, Allergan, Bayer, AbbVie, Urocure (I), NovoNordisk

No other potential conflicts of interest were reported.

Figures

Fig 1.
Fig 1.
Differences in sacrifice reporting by surgery type. (*) P < .05. (**) P < .005. (***) P < .001. BCS, breast-conserving surgery; BM, bilateral mastectomy; BMR, bilateral mastectomy with reconstruction; UM, unilateral mastectomy; UMR, unilateral mastectomy with reconstruction.

References

    1. Mariotto AB, Yabroff KR, Shao Y, et al. : Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103:117-1282011 - PMC - PubMed
    1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2017. CA Cancer J Clin 67:7-302017 - PubMed
    1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2018. CA Cancer J Clin 68:7-302018 - PubMed
    1. Yabroff KR, Lund J, Kepka D, et al. : Economic burden of cancer in the United States: Estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev 20:2006-20142011 - PMC - PubMed
    1. Lorenzoni L, Belloni A, Sassi F: Health-care expenditure and health policy in the USA versus other high-spending OECD countries. Lancet 384:83-922014 - PubMed

Publication types